Form 4: Zevra Therapeutics Director John B. Bode Reports Stock Purchase

Director John B. Bode of Zevra Therapeutics, Inc. [ZVRA] reported purchasing 10,000 shares of common stock at a weighted average price of $5.8661 on July 12, 2024, and disposing of 30,000 shares.

Summary

• On July 12, 2024, John B. Bode, a director of Zevra Therapeutics, Inc. [ZVRA], purchased 10,000 shares of common stock.
• The purchase was made at a weighted average price of $5.8661 per share.
• The prices for individual transactions ranged from $5.81 to $5.93.
• Following the reported transaction, Mr. Bode beneficially owns 30,000 shares.
• Mr. Bode also disposed of 30,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company, such as directors or officers, buy or sell the company's securities. These filings provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• It may influence investor sentiment depending on how the market interprets the director's stock purchase.

Key Dates